Autoimmune disease management has undergone revolutionary change with the introduction of Argenx's VYVGART, the trailblazing FcRn inhibitor that marked the beginning of a new therapeutic era. This groundbreaking medication has achieved outstanding clinical results in generalized myasthenia gravis (gMG) treatment and continues progressing through clinical development for immune...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Ελληνικά
Tiếng Việt